Sam S. Chang MD, MBA
Professor, Department of Urology; Patricia and Rodes Hart Professor of Urologic Surgery; Chief Surgical Officer, Vanderbilt Ingram Cancer Center; Chief, Division of Urologic Oncology, Vanderbilt University, Nashville, TennesseeAfter completing his education and training at Princeton University, Vanderbilt University, and Memorial Sloan-Kettering, Dr. Chang returned to Nashville and is currently Professor of Urologic Surgery. Focusing on urologic oncology and education, he has led efforts in integration of evidence-based medicine in clinical pathways, enhanced guidelines formulation, and improved cancer staging as chair of the AJCC GU Staging Panel and as a CoC member. He was the vice-chair of the AUA Guidelines on Noninvasive Bladder Cancer and the facilitator for the AUA Renal Cancer Follow-up Guidelines. Dr. Chang has authored more than 200 original publications. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, the CaPCURE Young Investigator Award, and has been twice named a Journal of Urology’s Best Reviewer. Dr. Chang was recently honored with the American Urological Association Gold Cystoscope Award.
Recent Contributions to PracticeUpdate:
- Process Map Analysis to Identify Institutional Causes of Delay to Radical Cystectomy for High-Risk Bladder Cancer
- Staging and Treatment Trends for Upper Tract Urothelial Carcinoma
- Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer Following Bacillus Calmette-Guérin Treatment
- Radio-Guided Sentinel Lymph Node Detection and Mapping in Invasive Urinary Bladder Cancer
- Risk of Intravesical Recurrence After Ureteroscopic Biopsy for Upper Tract Urothelial Carcinoma
- Safety of Active Surveillance for Low-Risk Non–Muscle Invasive Bladder Cancer
- Oncologic Outcomes After Anterior Exenteration for Muscle-Invasive Bladder Cancer in Women
- Resection of the Intramural Portion of the Distal Ureter During Transurethral Resection of Bladder Tumors
- Outcomes of Radical Cystectomy in Potential Candidates for Bladder Preservation Therapy
- Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection After Induction Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors